Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 1;63(11):1490-1493.
doi: 10.1093/cid/ciw539. Epub 2016 Aug 7.

The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma

Maria Del Castillo  1 , Fabian A Romero  2 , Esther Argüello  2 , Chrisann Kyi  3 , Michael A Postow  2 , Gil Redelman-Sidi  2
Affiliations

The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma

Maria Del Castillo et al. Clin Infect Dis. .

Abstract

The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticosteroids and/or infliximab.

Keywords: checkpoint blockade; immunotherapy; infection; melanoma.

PubMed Disclaimer

References

    1. Larkin J, Chiarion-Sileni V, Gonzalez R et al. . Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23–34. - PMC - PubMed
    1. Postow MA, Chesney J, Pavlick AC et al. . Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372:2006–17. - PMC - PubMed
    1. Robert C, Long GV, Brady B et al. . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320–30. - PubMed
    1. Robert C, Schachter J, Long GV et al. . Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372:2521–32. - PubMed
    1. Hodi FS, O'Day SJ, McDermott DF et al. . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711–23. - PMC - PubMed

MeSH terms